SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
CORALVILLE, Iowa, March 27, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences.
Details of KemPharm's presentation are as follows:
| Event: | 2nd Annual Neuroscience Biopartnering and Investment Forum | |
| Date: | Monday, March 27, 2017 | |
| Time: | 3:20 p.m. ET | |
| Location: | New York Academy of Sciences 7 World Trade Center 250 Greenwich St., 40th Floor (D Elevator Bank) New York, NY 10007 | |
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
